Clovis Oncology (CLVS) soars on upgrade

Clovis Oncology, Inc. CLVS shares climbed 11.1% to $86.00. Analysts at Goldman Sachs upgraded Clovis Oncology from neutral to buy and raised the price target from $60 to $66. Share volume was 988,000, compared to an all-day average of 550,000